Keen Vision Acquisition Corporation (“KVAC”) (Nasdaq: KVAC, KVACW) and Medera Inc., (“Medera”), a clinical-stage biotechnology company, announce that they have entered into a definitive merger agreement. Upon closing of the merger, which is expected to occur in the fourth quarter of 2024, the combined company is to be named Medera Inc. Medera Inc. is a clinical-stage biopharmaceutical company, focused on targeting difficult-to-treat and currently incurable diseases by developing next-generation gene- and cell-based approaches in combination with bioengineered human-based (including the exclusively available mini-Heart®) screening technology platform for disease modeling and drug discovery.
Read the full article: Medera Inc. to Be Listed on NASDAQ through a Merger Agreement with Keen Vision Acquisition Corporation //
Source: https://www.prnewswire.com/news-releases/medera-inc-to-be-listed-on-nasdaq-through-a-merger-agreement-with-keen-vision-acquisition-corporation-302238731.html